Liver Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with primary liver cancer (hepatocellular carcinoma, or HCC) confirmed either by biopsy or by standard clinical imaging guidelines
- People whose CT scan shows that bleeding from the tumor has stopped (hemostasis is present)
- People whose tumor has burst or ruptured, with blood pooling around the liver
- People who are receiving Lenvatinib and a PD-1 inhibitor (a type of immunotherapy) as their first round of systemic (whole-body) cancer treatment
- People who are receiving a procedure called TACE (a targeted treatment delivered directly to the liver's blood vessels) as a local therapy
- People whose liver function is rated as Child-Pugh class A or B, and whose general physical functioning is rated 0 or 2 on a standard scale used by doctors (ECOG scale)
- People who have no history of any other type of cancer
- People with a life expectancy of more than 3 months
- People who have agreed to take part in the trial
- People whose blood test results meet specific levels for white blood cells, red blood cells, platelets, liver enzymes, and kidney function (confirm with trial site for exact values)
Who may not be able to join:
- People whose liver cancer has come back after previous treatment (recurrent HCC)
- People whose tumor has not ruptured or burst
- People who are receiving Lenvatinib and a PD-1 inhibitor as a second (not first) round of systemic treatment
- People under 18 years old or over 75 years old
- People whose liver cancer has spread to more than five sites in the body
- People who have a history of hepatic encephalopathy (a condition where liver disease affects brain function) or gastrointestinal bleeding
- People with a life expectancy of less than 3 months
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Feng Duan, MD, Chinese PLA General Hospital
Phone: 86 19868000115
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Progression-Free-Survival (PFS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.